NASDAQ:PRAN - Prana Biotechnology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.04 -0.01 (-0.49 %)
(As of 08/20/2018 04:53 AM ET)
Previous Close$2.04
Today's Range$2.01 - $2.0489
52-Week Range$1.75 - $3.79
Volume1,284 shs
Average Volume47,697 shs
Market Capitalization$19.31 million
P/E Ratio-3.19
Dividend YieldN/A
Prana Biotechnology logoPrana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.

Receive PRAN News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio12.11
Quick RatioN/A


Trailing P/E Ratio-3.19
Forward P/E Ratio-2.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$100,000.00
Price / Sales181.56
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book1.01


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares8,900,000
Market Cap$19.31 million

Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."

When is Prana Biotechnology's next earnings date?

Prana Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, August, 30th 2018. View Earnings Estimates for Prana Biotechnology.

What price target have analysts set for PRAN?

1 analysts have issued 1 year price targets for Prana Biotechnology's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Prana Biotechnology's stock price to reach $4.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View Analyst Price Targets for Prana Biotechnology.

What is the consensus analysts' recommendation for Prana Biotechnology?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prana Biotechnology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prana Biotechnology.

Who are some of Prana Biotechnology's key competitors?

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the folowing people:
  • Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, Co-Founder, Exec. Chairman, CEO & MD (Age 63)
  • Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)
  • Ms. Dianne M. Angus, Chief Operating Officer (Age 58)
  • Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)
  • Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory Board

Has Prana Biotechnology been receiving favorable news coverage?

Media coverage about PRAN stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Prana Biotechnology earned a daily sentiment score of 0.20 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Prana Biotechnology.

How do I buy shares of Prana Biotechnology?

Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prana Biotechnology's stock price today?

One share of PRAN stock can currently be purchased for approximately $2.04.

How big of a company is Prana Biotechnology?

Prana Biotechnology has a market capitalization of $19.31 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-5,680,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. Prana Biotechnology employs 9 workers across the globe.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is LEVEL 2 369 ROYAL PARADE, PARKVILLE C3, 3052. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]

MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel